Roivant Sciences Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hi, good afternoon. Welcome to the Jefferies Healthcare Conference in London. My name is Dennis Ding, biotech analyst here at Jefferies. I have the wonderful pleasure of having Roivant CEO Matt Gline here.
Welcome. Thanks for having me.
It's great to be here again.
Maybe just to start off, just recap what has happened this year with Roivant. You guys have a lot of positive data and a lot of progress, so maybe just help set the stage there for us.
Yeah, thanks. It's been a quiet, uneventful 2026 for us. Not much to speak of.
Very quiet. No, look, it has been an amazing year in a way that makes you super appreciative and nervous about how you are going to follow it up.
It is almost hard to figure what has happened this year. We started off the year, this time last year at this conference, we had relatively recently announced the positive DM data, and were sort of on a path to getting that drug registered. We were a couple weeks away from our first Investor Day, looking forward. Early in 2026, we put out really nice data in our phase II study in cutaneous sarcoidosis. That was sort of kicking off the year, adding a proper second pillar for Brepo from an indication perspective. We then went on to also announce LPP as a phase II/III program that is ongoing. We failed in TED. We announced our period one positive D2T RA data that we have now finished that study, and the whole thing was successful, which is great.
We then later this year, back in September, announced really good data from our PH-ILD program, mosliciguat, and we launched LISRAYA. We got approved in August. I think I have not missed anything. I think that is what happened this year.
Yeah. Just that. Well, there's obviously a lot of talk about Oh, we also settled with Moderna.
That's right. That happened in March.
That's right. That's right. A very positive settlement. Maybe we could just start off with LISRAYA, because I feel like that's what a lot of investors are focused on in the near term. You guys had $31 million in revenue in the last quarter. Maybe talk a little bit about demand and what you're hearing from doctors and just the overall excitement that both patients and doctors are seeing on the ground.
Yeah, perfect. Look, we're obviously, we've said this a bunch of times, it's early days, it's hard to know at this stage, but super pleased with how the first six weeks that we reported went. Demand is good. Patients are, as best we can tell, excited. Docs are excited. So it's been a great early dynamic, as you said. Through 9/30, we had $31 million in sales. Fair amount of that was pharmacies buying drug in anticipation, but we've since dispensed all of it. So, a really nice first period and just good consistent demand through here. Feedback, I'd say, if anything, we had hundreds of patients on drug at the end of September. We had many hundreds of patients on paid drug in both cases, many of those patients on paid drug by November 9th.
We had many hundreds of prescribers, a good number of whom have only written one or two scripts, which is actually an awesome place to be at this stage of the launch. Because on the one hand, we have places like Johns Hopkins where we expect a lot of scripts. We've gotten a lot of scripts, a lot of enthusiasm from docs in some cases who were investigators on our study. But there's a long tail here of myositis centers and even some community rheumatology practices that are writing drug, where they're writing at this point what I would call test scripts. One or two patients have come through, it's a novel therapy, they're putting some patients on it, waiting to get feedback from those patients. And that's a great spot to be at this stage of the launch.
Those patients obviously haven't come back around yet, but they will later this year, early next year, into the first half of next year. As those patients cycle through, hopefully we'll be able to get a little bit of a positive feedback flywheel. So we feel really good about where we're at. Again, it's much too early to make any projection from here, and the payer dynamics are just starting to change in a way that we knew was going to happen. We're getting to see some real policies in place, and some are challenging, like the Centene policy that was announced even before we had the drug approved, that does require an IVIG step. But on the other hand, we have a Cigna Express Scripts policy that only requires a step through a steroid and one immunosuppressant.
We have another policy from Caremark that has similarly good sort of step criteria. Overall, feeling pretty solid, as much as you can know at this stage.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
